Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 3/20 | 0.43 |
| ▸ | HTR1B | P28222 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3244096 | 0.92 | HRH3 (0.56) | HRH3HTTDRD2SLC6A4L3MBTL3 | |
| SCHEMBL3244999 | 0.89 | HRH3 (0.60) | HRH3HTTL3MBTL3L3MBTL1 | |
| SCHEMBL3241196 | 0.88 | HRH3 (0.62) | HRH3HTTL3MBTL3L3MBTL1 | |
| SCHEMBL3236063 | 0.87 | DRD2 (0.58) | HRH3HTTADRA1DDRD2SLC6A4 | |
| SCHEMBL3239210 | 0.87 | HRH3 (0.58) | HRH3ADRA1DDRD2SLC6A4HTR2A | |
| SCHEMBL3236043 | 0.85 | HRH3 (0.55) | HRH3HTTL3MBTL3L3MBTL1 | |
| SCHEMBL3244778 | 0.84 | HRH3 (0.54) | HRH3HTTADRA1DDRD2SLC6A4 | |
| SCHEMBL3243051 | 0.84 | HRH3 (0.57) | HRH3HTTL3MBTL3L3MBTL1 | |
| SCHEMBL3244945 | 0.83 | HRH3 (0.57) | HRH3HTTL3MBTL3L3MBTL1 | |
| SCHEMBL3245572 | 0.81 | HRH3 (0.57) | HRH3HTTL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069331-B1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2010-05-05 | — | — | EP | disclosed |
| EP-2069331-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| US-7514433-B2 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | US | disclosed |
| WO-2008015125-A1 | 1H-INDOL-6-YL-PIPERAZIN-1-YL-METHANONE-DERIVATIVES FOR USE AS H3 RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080032976-A1 | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives | HTR6, HTR1A, HRH4 | HRH3 5/4885HTT 843/4885ADRA1D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.